Cornerstone Robotics ("CSR"), a leading global innovator in surgical robotics based in Hong Kong, China, is pleased to announce its Sentire® Endoscop...
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Innovent Biologics, Inc. ("I...
European Medicines Agency (EMA) has adopted a positive opinion recommending approval of nerandomilast for the treatment of idiopathic pulmonary fibrosis ...
Joenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS),...
Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced that it has received...
Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced so...
The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s re...
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Lev...
From advanced biologics and cell therapies to increasingly stringent regulatory expectations, today’s pharmaceutical manufacturing environments dem...
Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stag...
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib) Once-daily Jakafi XR was shown to provide consisten...
Central nervous system (CNS) cancers remain among the most difficult diseases to treat in oncology, with limited therapeutic options, complex deliv...
Santhera Pharmaceuticals (SIX: SANN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA...
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies ...
© 2026 Biopharma Boardroom. All Rights Reserved.
